Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days

Jul 20 2018

• By Joseph Haas

Cancer cells on scientific background.3d illustration

Related Content

Agios' IDH Inhibitors Show Their Mettle At ASH

Dec 12 2017

Novartis' Rydapt: Two Indications, Two Prices

May 01 2017

AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

Jan 06 2017

Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market

Jun 18 2018

Celgene, Agios Ready For Enasidenib Launch After Early Approval

Aug 01 2017

Related Companies

Agios Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Novartis AG

Daiichi Sankyo Co., Ltd.

Abbott

Additional Topics

Approvals Commercial Business Strategies Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window